IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed?
IDEAYA Biosciences has announced a clinical collaboration with Genentech to test its investigational MTA-cooperative PRMT5 inhibitor, IDE892, in combination with Genentech's KRAS G12D inhibitor GDC-7035 for a specific type of pancreatic cancer. This partnership is seen as external validation for IDEAYA's precision oncology platform and its focus on combination regimens in MTAP-deleted tumors. While the collaboration diversifies partnership support and strengthens confidence in IDEAYA's strategy, it also introduces another early-stage program that will require significant time and capital.
IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed?
IDEAYA Biosciences' stock rose 5.2% following news of a clinical collaboration with Genentech. The partnership involves testing IDEAYA's investigational MTA-cooperative PRMT5 inhibitor, IDE892, in combination with Genentech's KRAS G12D inhibitor GDC-7035 for a specific pancreatic cancer subgroup. This collaboration validates IDEAYA's precision oncology platform and combination strategy, though near-term catalysts remain focused on existing pipeline assets and addressing ongoing cash burn.
Genentech doubles down on IDEAYA’s PRMT5 strategy with KRAS G12D combo
IDEAYA Biosciences and Genentech have announced a clinical collaboration to evaluate IDEAYA's IDE892, a PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor GDC-7035 for patients with MTAP-deleted and KRAS G12D-mutated pancreatic ductal adenocarcinoma. Genentech will fund the trial, with each company retaining commercial rights to their respective compounds. This collaboration marks IDEAYA's second with the Roche Group in 2026 for IDE892, building on a previous partnership for a pan-RAS inhibitor combination.
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com
IDEAYA Biosciences Inc. has announced a clinical collaboration with Genentech to evaluate IDE892 in combination with GDC-7035 for patients with pancreatic ductal adenocarcinoma who have both an MTAP-deletion and a KRAS G12D mutation. This trial targets a subset of pancreatic cancer patients who currently lack approved targeted treatment options. Genentech will sponsor the study, while IDEAYA will supply its investigational compound IDE892, with both companies retaining commercial rights to their respective therapies.
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Genentech to evaluate IDE892, their MTA-cooperative PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor (RG6620) for treating MTAP-deleted, KRAS G12D-mutant pancreatic cancer. Genentech will sponsor the trial, with joint governance overseeing the study, and IDEAYA will supply IDE892. This collaboration aims to address the high unmet medical need for patients with co-occurring MTAP deletions and KRAS G12D mutations in pancreatic ductal adenocarcinoma.
IDEAYA Biosciences (IDYA) Reports Second Quarter Results, Is The Valuation Still Justified?
IDEAYA Biosciences (IDYA) recently reported Q2 2026 results with $8.86 million in revenue and a net loss of $112.45 million, leading investors to re-evaluate the stock despite a strong 12-month performance. The company's current Price-to-Sales (P/S) ratio of 15.1x is considered expensive compared to industry averages and an estimated fair P/S of 4.3x, suggesting potential overvaluation based on revenue. However, a Discounted Cash Flow (DCF) model indicates the stock might be undervalued at its current price, presenting a mixed signal for investors.
IDEAYA Biosciences (IDYA) Reports Second Quarter Results, Is The Valuation Still Justified?
IDEAYA Biosciences (IDYA) recently reported its second-quarter 2026 results, showing increased revenue but wider net losses. The stock has seen significant momentum over the past year, prompting a re-evaluation of its valuation. While a Discounted Cash Flow model suggests undervaluation, its Price-to-Sales multiple indicates it is expensive compared to industry benchmarks, creating a mixed picture for investors.
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA
Bank of America Corp DE has increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 4.3% in the first quarter, holding over 942,000 shares valued at $31.39 million. Institutional investors and hedge funds collectively own 98.29% of the company. Despite reporting a quarterly loss, IDEAYA Biosciences saw significant revenue growth year-over-year, and analysts maintain a "Moderate Buy" consensus with an average price target of $50.12.
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA
Walleye Capital LLC has acquired 386,183 shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, a new stake valued at approximately $14.4 million. This purchase represents 0.44% of IDEAYA Biosciences. Despite a reported quarterly loss of $1.22 per share, institutional ownership of the company stands at 98.29%, and analysts maintain a "Moderate Buy" consensus with an average price target of $50.12.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages
IDEAYA Biosciences (NASDAQ:IDYA) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $50.13, significantly above its current share price of $36.30. The company's recent quarterly results showed revenue exceeding expectations but missed on earnings per share. Institutional ownership is very high at 98.29%, while insiders own 4.70% of the stock.
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, missing estimates, though revenue increased significantly year-over-year. Institutional ownership is notably high at 98.29%, with some large firms establishing new positions, while a company accounting officer recently sold shares.
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants
Baker Bros. Advisors and its related entities have disclosed a 5.2% beneficial ownership stake in IDEAYA Biosciences, Inc. (IDYA), totaling 5,010,030 shares based on 96,375,637 shares outstanding as of June 30, 2026. The firm also holds prefunded warrants with a low exercise price but cannot currently exercise them due to an initial 4.99% ownership cap, which can be adjusted up to 19.99% after a 61-day waiting period. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment.
IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026
IDEAYA Biosciences (IDYA) reported a short interest of 10.11 million shares as of July 31, 2026, marking a 5.64% increase from the previous period. This represents 12.08% of the public float and a short interest ratio of 13.2 days to cover. The article provides a detailed historical overview of IDYA's short interest data, comparing it to competitors and explaining key short-selling metrics.
How (IDYA) Movements Inform Risk Allocation Models
This article from Stock Traders Daily discusses how Ideaya Biosciences Inc. (NASDAQ: IDYA) movements inform risk allocation models. It highlights key findings such as a strong near-term sentiment possibly leading to a long-term positive bias, and an exceptional 49.4:1 risk-reward setup. The analysis provides institutional trading strategies including long, breakout, and short positions based on AI-generated signals for different time horizons.
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Q2 Losses And IDE892 Trial Expansion
IDEAYA Biosciences reported Q2 2026 results with $8.86 million in revenue and a widened net loss of $112.45 million, or $1.22 per share. Despite the losses, the company advanced IDE892 into Part 2 monotherapy expansion for MTAP-deleted solid tumors, which is a positive development for its precision oncology pipeline. The investment narrative for IDEAYA hinges on clinical and regulatory milestones rather than near-term profitability, with the IDE892 expansion sharpening the long-term opportunity but also adding potential execution and financing risks due to rising development costs.
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
LifeSci Capital has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US) and maintained its target price at $58. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
IDEAYA Biosciences (IDYA) Stock Could Be Fully Valued After Trial Progress
IDEAYA Biosciences (IDYA) stock has delivered a 61.0% return over five years, but its current P/S ratio of 14.9x suggests it might be overvalued compared to the biotech industry average and a fair P/S of 4.3x implied by the model. While progress in its oncology pipeline could support future revenue, the stock's valuation appears to already price in a significant amount of future success, warranting caution for investors. The article emphasizes that the stock's future movement depends on whether current expectations are sustainable or if the valuation will normalize.
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history
This article provides a detailed financial overview of IDEAYA Biosciences, Inc. (IDYA), including its current stock price, historical data, and analyst ratings. It highlights the company's focus on developing targeted therapeutics for oncology and lists its key drug candidates and strategic alliances. The report also includes performance metrics, earnings trends, and valuation measures for IDYA.
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership
IDEAYA Biosciences recently reported a wider Q2 2026 net loss of US$112.45 million, or US$1.22 per share, and an overall wider six-month loss compared to the previous year. Despite this, the company is advancing its precision oncology pipeline, initiating a monotherapy expansion for IDE892 and partnering with Roche for combination regimens in MTAP-deleted pancreatic cancer. The article suggests that while the company's valuation is high and it faces significant cash burn, these clinical advancements and partnerships could reshape its investment narrative, emphasizing the importance of trial progress over current earnings.
IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary
IDEAYA Biosciences reported its second-quarter 2026 results, showing collaboration revenue of $8.86 million and a net loss of $(112.45) million, or $(1.22) diluted EPS, due to increased R&D and commercial preparation. The company highlighted positive Phase 2/3 clinical trial results for darovasertib, with an NDA submission planned for H2 2026, and ongoing advancements in its pipeline. Financial highlights include a significant increase in revenue from the prior year and a worsening net loss.
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37
LEERINK PARTNERS has cut its target price for IDEAYA BIOSCIENCES, INC. (IDYA.O) from $37 to $31. This information was reported by Reuters on August 5, 2026. The article does not provide further details or analysis regarding the reasons for the price target reduction.
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37
Leerink Partners has decreased its target price for IDEAYA Biosciences, Inc. (IDYA.O) from $37 to $31. This adjustment was reported by Reuters on August 5, 2026, at 12:21 PM. The article provides this key financial action without further elaborating on the reasons behind the target price cut.
IDEAYA Biosciences (IDYA) Stock Faces Loss Pressure Despite Revenue Traction
IDEAYA Biosciences (IDYA) stock saw a modest increase after its Q2 2026 earnings report, which highlighted significant revenue growth but also widening net losses. While the company achieved substantial revenue traction and secured new funding, its increasing cash burn and lack of a clear path to profitability raise concerns for investors. The article suggests that despite positive developments in its pipeline, the high P/S ratio and deep losses could signal a value trap.
IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend
IDEAYA Biosciences reported Q2 2026 collaboration revenue of $8.9 million and a net loss of $112.5 million, with R&D expenses significantly increasing to $108.7 million for the quarter. The company strengthened its liquidity through a June 2026 follow-on offering and at-the-market sales, boosting cash, cash equivalents, and marketable securities to approximately $1.24 billion, which is expected to fund operations for at least 12 months. IDEAYA continues to heavily invest in its precision oncology pipeline, including darovasertib for uveal melanoma and multiple ADC and synthetic lethality programs.
Uveal melanoma trial reports 6.9 months progression-free vs. 3.1
IDEAYA Biosciences (IDYA) announced positive results from its registrational Phase 2/3 OptimUM-02 trial for darovasertib plus crizotinib in metastatic uveal melanoma, meeting its primary endpoint with a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the investigator's choice arm. The company is proceeding with an NDA filing under the FDA’s real-time oncology review program, targeting completion in the second half of 2026. IDEAYA also reported strong financial results for Q2 2026, ending the quarter with $1.24 billion in cash, cash equivalents, and marketable securities, extending its cash runway guidance into 2030.
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion
IDEAYA Biosciences (IDYA) reported a Q2 2026 net loss of $112.5 million ($1.22 per share) on collaboration revenue of $8.9 million, up from the prior quarter. The company announced its cash, cash equivalents, and marketable securities reached $1.24 billion, with cash runway guidance into 2030 remaining unchanged. IDEAYA also reported that its OptimUM-02 trial met its primary endpoint, leading to an NDA filing, and detailed upcoming data presentations and a new collaboration with Roche for a Phase 1 combination trial.
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences announced its second-quarter 2026 financial results and provided a business update. The company's registrational OptimUM-02 trial for darovasertib combination in metastatic uveal melanoma met its primary endpoint, with an NDA filing underway. IDEAYA also reported a strong financial position with approximately $1.24 billion in cash, cash equivalents, and marketable securities, projecting a cash runway into 2030.
IDEAYA Biosciences reports Q2 2026 net loss $112.5M; cash $1.24B after $323M offering
IDEAYA Biosciences reported a net loss of $112.5 million for Q2 2026, ending the period with $1.24 billion in cash, cash equivalents, and marketable securities after a $323 million public offering. The company's OptimUM-02 trial met its primary endpoint, leading to an NDA filing under the FDA RTOR program, and various other pipeline programs are advancing with several clinical data presentations and trial initiations planned.
IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises
IDEAYA Biosciences (IDYA) reported a wider loss of $1.22 per diluted share in Q2, compared to the previous quarter. Despite the increased loss, the company experienced a rise in revenue during the same period. This article provides a brief overview of IDEAYA's Q2 financial performance.
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M
IDEAYA Biosciences, Inc. (IDYA) announced its Q2 revenue of $8.9 million, surpassing FactSet's estimate of $8.0 million. This news comes alongside other recent updates for the company, including Wedbush adjusting its price target to $60 and maintaining an Outperform rating, and the company's Q2 loss widening while revenue increased. IDEAYA Biosciences is a medicine oncology company focused on developing transformative therapies for cancer.
Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA
Dimensional Fund Advisors LP significantly increased its stake in IDEAYA Biosciences, Inc. (IDYA) by 42% in Q1, now holding 1.33 million shares valued at $44.4 million. Other institutional investors like State Street and Janus Henderson also boosted their positions, with institutional ownership reaching 98.29%. Despite a recent EPS miss, analysts maintain a "Moderate Buy" rating with a consensus target price of $50.25, while one insider recently sold shares.
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced inducement grants of stock options to three new employees. These grants were approved by the Compensation Committee of the company's Board of Directors and are made under Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employees entering into employment with IDEAYA. The stock options are exercisable for 31,500 shares of common stock, vest over four years, and have a ten-year term.
IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per share
IDEAYA Biosciences issued inducement stock options for 260,200 shares to 14 new employees on July 30, 2026. The exercise price for these options is $36.4 per share, matching the stock's Nasdaq closing price on the grant date. These awards have a 10-year term, with 25% vesting after one year and the remainder vesting monthly over the subsequent three years.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced that its Compensation Committee granted stock options for 260,200 shares of common stock to fourteen new employees on July 30, 2026. These grants were made under the 2023 Inducement Plan as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $36.40 per share, a 10-year term, and vest over four years, subject to continued service.
14 New IDEAYA Hires Granted Stock Options at $36.40
IDEAYA Biosciences (NASDAQ: IDYA) has granted non-qualified stock options for an aggregate of 260,200 shares to fourteen newly hired employees. These grants were made under the 2023 Employment Inducement Incentive Award Plan, with an exercise price of $36.40 per share, equal to the closing price on July 30, 2026. The options have a 10-year term and will vest over four years, subject to continued employment.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced that its Compensation Committee granted non-qualified stock options to fourteen newly hired employees. These grants, totaling 260,200 shares, were made on July 30, 2026, under the company's 2023 Employment Inducement Incentive Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $36.40 per share, a 10-year term, and vest over four years.
Will IDEAYA’s (IDYA) IDE892 Combo Strategy in MTAP‑Deleted Cancers Reshape Its Targeted Oncology Narrative?
IDEAYA Biosciences is expanding its Phase 1/2 trial for IDE892, a PRMT5 inhibitor targeting MTAP-deleted solid tumors, into monotherapy expansion. This move positions IDE892 as a combination backbone for various cancer treatments, potentially reshaping IDEAYA's investment narrative by adding a second pillar to its precision-oncology platform. While this strategy offers significant upside potential in an unmet medical need, it also introduces clinical complexity and reinforces the company's aggressive spending and loss-making status.
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
Mizuho Securities has reiterated its Buy rating on IDEAYA Biosciences (IDYA.US), maintaining a target price of $50. This continued endorsement suggests the firm's confidence in the biotechnology company's future performance and valuation. The decision indicates that Mizuho sees strong potential for growth or continued stability in IDEAYA Biosciences.
IDEAYA Biosciences Inc (IDYA) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for IDEAYA Biosciences Inc (IDYA), covering operating, investing, and financing activities. It includes year-over-year percentage changes and absolute financial figures for various cash flow components. The report also features a FAQ section explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow, along with specific figures for IDYA.
IDEAYA Biosciences (IDYA) Advances IDE892 Trial, Is The Upside Already Priced In?
IDEAYA Biosciences (IDYA) has moved its IDE892 trial into Part 2 monotherapy expansion for MTAP-deleted solid tumors, showcasing positive momentum with recent share price gains. While the company's 15.5x price-to-sales ratio is considered overvalued compared to the broader US biotechs industry, it is undervalued relative to its peer group and a discounted cash flow model suggests potential upside. Investors are encouraged to assess the balance of risks, including ongoing losses and trial uncertainties, against potential rewards.
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
LifeSci Capital has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US), concurrently maintaining a target price of $62 for the company's stock. This indicates a continued positive outlook from the firm regarding IDEAYA Biosciences' future performance.
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated Part 2 monotherapy expansion of its Phase 1/2 clinical trial for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor. This expansion focuses on MTAP-deleted solid tumors, specifically non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), building on its unique selective binding properties and favorable drug characteristics. IDEAYA is also exploring combination therapies with IDE397 and Roche's pan-RAS inhibitor RG6505, and advancing a third program targeting CDKN2A, aiming to address the significant unmet medical need for patients with MTAP-deleted cancers.
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of IDEAYA Biosciences Inc (IDYA)'s financial data, focusing on its revenue breakdown. It notes that detailed segment and regional revenue data has not yet been disclosed by the company. The available information indicates a reported revenue of $218.71M for the United States, with other data pending release for various fiscal periods.
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of IDEAYA Biosciences Inc (IDYA), noting its current valuation score of 8.91 and ranking within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, highlighting its position relative to recent highs and lows. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of IDEAYA Biosciences Inc (IDYA), indicating a current financial score of 5.99, ranking 302 out of 386 in its industry. The company's financial status is stable, but its operating efficiency is low, with several key financial metrics not yet disclosed.
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IDEAYA Biosciences Inc (IDYA), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 24, 2026, the stock's price momentum score is 3.63, suggesting suitability for range-bound swing trading with resistance at $39.32 and support at $32.75. The analysis indicates a "Neutral" signal overall, with mixed signals from individual indicators and moving averages.
IDYA|IDEAYA Biosciences Inc|Price:35.380|Chg%:-0.850
This article provides a detailed financial overview of IDEAYA Biosciences Inc (IDYA), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators, earnings history, and analyst ratings, presenting data up to FY2026Q1 and addressing frequently asked questions about the company's financials.
ETFs Investing in IDEAYA Biosciences, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of IDEAYA Biosciences, Inc. (IDYA). It provides a detailed table of these funds, including their market value, weight of IDYA in their holdings, issuer, management style, focus, expense ratio, assets under management (AUM), and performance metrics like price change and NAV total return. The ETFs cover different investment focuses such as health care, small-cap, extended market, and biotechnology themes.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced that its Compensation Committee granted non-qualified stock options for 150,000 shares to a new employee on August 19, 2024. These options, granted under the 2023 Employment Inducement Incentive Award Plan, serve as an inducement for the individual to join the company, in line with Nasdaq Listing Rule 5635(c)(4). The exercise price is $39.06 per share, matching the closing price on the grant date, and the options will vest over four years.
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
IDEAYA Biosciences announced it will present three abstracts at the 2026 European Society of Medical Oncology (ESMO) meeting, showcasing updated data from its darovasertib clinical trials for uveal melanoma (OptimUM-02, OptimUM-01, OptimUM-09). Additionally, its partner Hengrui Pharma will present long-term results from the Phase 1 study of IDE849 (SHR-4849) in small cell lung carcinoma and other neuroendocrine carcinomas. The company highlighted darovasertib’s potential across the uveal melanoma patient journey and IDE849’s potential as a best-in-class DLL3 TOP1 ADC, with a registrational trial for IDE849 targeted to initiate by year-end.
